Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
3000 participants
OBSERVATIONAL
2023-01-01
2033-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Belgian Registry on Coronary Function Testing
NCT06089031
Impact of Coronary Sinus Flow Reducer on Coronary Microcirculation and Myocardial Ischemia
NCT06266065
Symptoms of Acute Coronary Syndrome in Medical Regulation
NCT05902130
The DISCOVER INOCA Prospective Multi-center Registry
NCT05288361
Evaluation of Patients With Known or Suspected Heart Disease
NCT00001313
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In this long-term follow-up registry we plan to collect data on clinical status, standard laboratory results including lipidogram values, NTproBNP values after specific interventions (in.ex. TAVI implantation, SGLT2inh prescripition), bleeding complications, and every major cardiovascular event, including cardiovascular death and all cause death.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Acute coronary syndrome - ACS
patients who were diagnosed with acute coronary syndrome: STEMI, non-STE ACS - NSTEMI and unstable angina, who underwent coronary angiography and were prescribed with optimal medicament therapy
SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Transcatheter aortic valve implantation - TAVI
patients with aortic stenosis who underwent transcatheter percotaneous implantation of the arteficial aortic valve
SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Venous thromboembolism - VTE
patients with pulmonary embolism and deep vein thrombosis, with a focus on those who underwent thromboaspiration due to high or medium-high risk pulmonary embolism
SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Heart failure with SGLT2 inhibitor therapy included - HF-SGLT2
patients with heart failure with reduced, mid-reduced and preserved systolic function who were prescribed with a SGLT-2 inhibitor therapy, and other optimal medicament therapy for HF
SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Cardiac implantable electronic device - CIED
patients who were implanted with a cardiac implantable electronic device: pacemaker, conduction system pacing device, cardioverter-defibrilator or cardiac resynchronization therapy with or without defibrilator option
SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Arrhythmias
patients who underwent electrophysiology study, including PVI for atrial fibrillation, as well as SVT ablations, and ventricular arrhythmia ablation (both premature ventriclar beats and ventricular tachycardia ablation in ischsmic and non-ischemic cardiomyopathy).
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SGLT-2 inh therapy, CIED implantation, thromboaspiration,
long-term follow up and observation of patients treated in Cardiology department in the tertiary center and University hospital
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Dubrava
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ivan Zeljkovic
M.D., Ph.D., Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ivana Jurin, M.D.
Role: STUDY_CHAIR
Dubrava University Hospital
Irzal Hadzibegovic, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Nikola Pavlovic, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Marin Pavlov, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Mario Udovicic, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Danijel Unic, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Ana Jordan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Tomislav Sipic, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Diana Rudan, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dubrava University Hospital
Sime Manola, M.D.
Role: STUDY_DIRECTOR
Dubrava University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dubrava University Hospital
Zagreb, , Croatia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DUH-012017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.